Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Completed · Phase 1/Phase 2
Conditions studied: Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Prostatic Cancer, Castration-Resistant
In brief
This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).
Key facts
- Study ID
- NCT04381832
- Run by
- Arcus Biosciences, Inc.
- People needed
- 173
- Starts
- 2020-07-07
- Expected to finish
- 2024-08-30
- Last updated by the study team
- 2025-07-22
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- The Oncology Institute of Hope & Innovation — Cerritos, California, United States
- The University of California, Los Angeles — Encino, California, United States
- The University of California, Irvine Medical Center — Orange, California, United States
- Florida Cancer Specialists South — Sarasota, Florida, United States
- Florida Cancer Specialists North — St. Petersburg, Florida, United States
- Florida Cancer Specialists Panhandle — Tallahassee, Florida, United States
- Florida Cancer Specialists East — West Palm Beach, Florida, United States
- Northwestern University Feinberg School of Medicine — Chicago, Illinois, United States
- Affinity Health Hope & Healing Cancer Services — Hinsdale, Illinois, United States
- Johns Hopkins University — Baltimore, Maryland, United States
- New York University, Langone Health — New York, New York, United States
- Wilmot Cancer Institute Oncology, University of Rochester — Rochester, New York, United States
- Cleveland Clinic — Cleveland, Ohio, United States
- Tennessee Oncology - Chattanooga — Chattanooga, Tennessee, United States
- Tennessee Oncology - Nashville — Nashville, Tennessee, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Medical Oncology Associates, PS (dba Summit Cancer Centers) — Spokane, Washington, United States
- Juravinski Cancer Center — Hamilton, Ontario, Canada
- Centre hospitalier de l'Université de Montréal (CHUM) Centre de Recherche — Montreal, Quebec, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.